Use of favipiravir in treatment of coronavirus infection

Abstract

The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.

What is claimed is: 
     
         1 . A method for treating and/or preventing a disease in a mammal in need, the method comprising administering to the mammal in need a therapeutically and/or prophylactically effective amount of a pharmaceutical composition comprising a compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, 
       
         
           
           
               
               
           
         
         or a compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, wherein the disease is a disease caused by a coronavirus. 
       
     
     
         2 . The method according to  claim 1 , wherein the coronavirus is SARS coronavirus (SARS-CoV) or SARS-CoV-2. 
     
     
         3 . The method according to  claim 2 , wherein the coronavirus is SARS-CoV-2. 
     
     
         4 . The method according to  claim 1 , wherein the disease caused by the coronavirus is a disease caused by a SARS-CoV-2, namely COVID-19. 
     
     
         5 . The method according to  claim 1 , wherein the disease caused by the coronavirus is atypical pneumonia caused by a SARS coronavirus (SARS-CoV). 
     
     
         6 . The method according to  claim 1 , wherein the disease caused by the coronavirus is a respiratory disease. 
     
     
         7 . The method according to  claim 1 , wherein the disease caused by the coronavirus is simple infection, pneumonia, acute respiratory infections, severe acute respiratory infection (SARI), hypoxic respiratory failure, acute respiratory distress syndrome, sepsis, septic shock, or severe acute respiratory syndrome (SARS). 
     
     
         8 . The method according to  claim 7 , wherein the simple infection is fever, cough and/or sore throat. 
     
     
         9 . The method according to  claim 1 , wherein the mammal is bovine, equine, caprid, suidae, canine, feline, rodent or primate. 
     
     
         10 . The method according to  claim 9 , wherein the mammal is human, cat, dog or pig. 
     
     
         11 . A method for inhibiting the replication or reproduction of coronavirus in a mammal in need, the method comprising administering to the mammal in need a therapeutically and/or prophylactically effective amount of a pharmaceutical composition comprising a compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, 
       
         
           
           
               
               
           
         
         or a compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, wherein the disease is a disease caused by a coronavirus. 
       
     
     
         12 . The method according to  claim 11 , wherein the coronavirus is SARS coronavirus (SARS-CoV) or SARS-CoV-2. 
     
     
         13 . The method according to  claim 12 , wherein the coronavirus is SARS-CoV-2. 
     
     
         14 . The method according to  claim 11 , wherein the disease caused by the coronavirus is a disease caused by a SARS-CoV-2, namely COVID-19. 
     
     
         15 . The method according to  claim 11 , wherein the disease caused by the coronavirus is atypical pneumonia caused by a SARS coronavirus (SARS-CoV). 
     
     
         16 . The method according to  claim 11 , wherein the disease caused by the coronavirus is a respiratory disease. 
     
     
         17 . The method according to  claim 11 , wherein the disease caused by the coronavirus is simple infection, pneumonia, acute respiratory infections, severe acute respiratory infection (SARI), hypoxic respiratory failure, acute respiratory distress syndrome, sepsis, septic shock, or severe acute respiratory syndrome (SARS). 
     
     
         18 . The method according to  claim 17 , wherein the simple infection is fever, cough and/or sore throat. 
     
     
         19 . The method according to  claim 11 , wherein the mammal includes bovine, equine, caprid, suidae, canine, feline, rodent, primate. 
     
     
         20 . The method according to  claim 19 , wherein the mammal is human, cat, dog or pig.